Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker JAZZ · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy NCT06113237 · Maternal Complications, Pregnancy Complication Epidiolex | JAZZ Jazz Pharmaceuticals | — | Recruiting | 50 | Aug 31, 2033 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclon… NCT07723963 · Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo | JAZZ Jazz Pharmaceuticals | Phase 2/3 | Recruiting | 260 | Aug 1, 2028 | Registry ↗ |
| Nov 9, 2026 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082 · Central Nervous System Neoplasms, Glioblastoma ONC206 | JAZZ Jazz Pharmaceuticals | Phase 1 | Active, not recruiting was recruiting | 35 | Mar 31, 2027 | Registry ↗ |
| Nov 6, 2026 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-S… NCT07459634 · Extensive-stage Small-cell Lung Cancer Lurbinectedin, Durvalumab | JAZZ Jazz Pharmaceuticals | Phase 2 | Recruiting | 50 | Aug 4, 2029 | Registry ↗ |
| Nov 5, 2026 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refracto… NCT05734066 · Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma Lurbinectedin | JAZZ Jazz Pharmaceuticals | Phase 1/2 | Recruiting | 60 | Jan 28, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in H… NCT07813663 · Healthy Participants JZP269, Placebo | JAZZ Jazz Pharmaceuticals | Phase 1 | Recruiting was not yet recruiting | 212 | Feb 27, 2027 | Registry ↗ |
| Nov 4, 2026 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 · Breast Cancer, Gastric Cancer Zanidatamab | JAZZ Jazz Pharmaceuticals | Phase 2 | Recruiting | 200 | Dec 31, 2026 | Registry ↗ |
| Nov 4, 2026 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing… NCT03929666 · HER2-expressing Gastrointestinal Cancers, Including Gastroe… ZW25 (Zanidatamab), Capecitabine | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 74 | Aug 30, 2025 | Registry ↗ |
| Nov 3, 2026 | Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setti… NCT05772429 · Seizures Epidiolex | JAZZ Jazz Pharmaceuticals | — | Completed was active, not recruiting | 158 | Aug 25, 2026 | Registry ↗ |
| Oct 29, 2026 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma NCT07533942 · Meningioma JZP3507 | JAZZ Jazz Pharmaceuticals | Phase 2 | Recruiting | 30 | Oct 25, 2028 | Registry ↗ |
| Oct 29, 2026 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma NCT07282587 · Advanced Pheochromocytoma and Paraganglioma, PCPG ONC206, ONC206: Dose 1 | JAZZ Jazz Pharmaceuticals | Phase 2 | Recruiting | 90 | Dec 15, 2028 | Registry ↗ |
| Oct 29, 2026 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP92… NCT07233239 · Focal Seizures CBD-OS | JAZZ Jazz Pharmaceuticals | Phase 1 | Recruiting | 100 | Nov 29, 2027 | Registry ↗ |
| Oct 29, 2026 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HE… NCT07102381 · HER2-positive Breast Cancer, Breast Cancer Zanidatamab, Paclitaxel | JAZZ Jazz Pharmaceuticals | Phase 2 | Recruiting | 125 | Dec 29, 2027 | Registry ↗ |
| Oct 28, 2026 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy f… NCT06282575 · Biliary Tract Cancer Zanidatamab, Cisplatin | JAZZ Jazz Pharmaceuticals | Phase 3 | Recruiting | 286 | Dec 1, 2028 | Registry ↗ |
| Oct 26, 2026 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA NCT07780968 · Esophageal Cancer, GastroEsophageal Cancer Zanidatamab | JAZZ Jazz Pharmaceuticals | — | Not yet recruiting | 300 | Oct 1, 2031 | Registry ↗ |
| Oct 23, 2026 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Hea… NCT07377539 · Healthy Participants JZP047, Placebo | JAZZ Jazz Pharmaceuticals | Phase 1 | Active, not recruiting | 86 | Nov 30, 2026 | Registry ↗ |
| Oct 22, 2026 | A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults… NCT07728097 · Lennox-Gastaut Syndrome Cannabidiol Oral Solution | JAZZ Jazz Pharmaceuticals | Phase 4 | Not yet recruiting | 40 | Dec 28, 2028 | Registry ↗ |
| Oct 20, 2026 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With… NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma Zanidatamab, Tislelizumab | JAZZ Jazz Pharmaceuticals | Phase 3 | Active, not recruiting | 920 | Jul 15, 2026 | Registry ↗ |
| Oct 8, 2026 | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With… NCT07625280 · Narcolepsy, Idiopathic Hypersomnia Xywav, Placebo | JAZZ Jazz Pharmaceuticals | Phase 3 | Recruiting | 120 | Dec 23, 2027 | Registry ↗ |
| Sep 24, 2026 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant NCT04224272 · HER2+/HR+ Breast Cancer ZW25 (Zanidatamab), Palbociclib | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 51 | Apr 28, 2023 | Registry ↗ |
| Sep 10, 2026 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harb… NCT05557045 · Advanced Cancer, Metastatic Cancer JZP815 | JAZZ Jazz Pharmaceuticals | Phase 1 | Active, not recruiting | 98 | Apr 1, 2028 | Registry ↗ |
| Aug 27, 2026 | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes… NCT05875974 · Idiopathic Hypersomnia, Narcolepsy JZP258 (XYWAV) | JAZZ Jazz Pharmaceuticals | Phase 4 | Completed | 199 | Mar 13, 2025 | Registry ↗ |
| Aug 26, 2026 | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidio… NCT05044819 · Lennox Gastaut Syndrome, Dravet Syndrome Cannabidiol | JAZZ Jazz Pharmaceuticals | Phase 4 | Active, not recruiting | 154 | Aug 1, 2027 | Registry ↗ |
| Jul 24, 2026 | A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE NCT07723976 · Developmental and Epileptic Encephalopathy (DEE) CBD-OS, Placebo | JAZZ Jazz Pharmaceuticals | Phase 3 | Not yet recruiting | 120 | Sep 4, 2029 | Registry ↗ |
| Jul 1, 2026 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Ca… NCT05027139 · HER2-expressing Cancers Zanidatamab, Evorpacept | JAZZ Jazz Pharmaceuticals | Phase 1/2 | Completed | 52 | Aug 29, 2025 | Registry ↗ |
| Jun 3, 2026 | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Stud… NCT05485831 · Lennox Gastaut Syndrome, Dravet Syndrome Epidiolex 100 mg/mL Oral Solution | JAZZ Jazz Pharmaceuticals | — | Active, not recruiting | 111 | Feb 2027 | Registry ↗ |
| Apr 27, 2026 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy… NCT05864846 · Tuberous Sclerosis Complex Associated Neuropsychiatric Dise… Cannabidiol Oral Solution [Epidiolex] | JAZZ Jazz Pharmaceuticals | Phase 4 | Completed | 79 | Apr 6, 2026 | Registry ↗ |
| Apr 24, 2026 | A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participa… NCT05869773 · Narcolepsy JZP258 | JAZZ Jazz Pharmaceuticals | Phase 4 | Completed | 155 | Feb 25, 2025 | Registry ↗ |
| Apr 16, 2026 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) NCT05580562 · H3 K27M, Glioma Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo | JAZZ Jazz Pharmaceuticals | Phase 3 | Recruiting | 510 | Jun 2028 | Registry ↗ |
| Apr 6, 2026 | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With… NCT06961266 · Narcolepsy JZP441, Matching Placebo | JAZZ Jazz Pharmaceuticals | Phase 1 | Terminated | 6 | Jan 29, 2026 | Registry ↗ |
| Feb 27, 2026 | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cel… NCT04894591 · Extensive-stage Small-cell Lung Cancer Zepzelca | JAZZ Jazz Pharmaceuticals | — | Completed | 272 | Jun 4, 2025 | Registry ↗ |
| Feb 10, 2026 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With P… NCT06435429 · Metastatic HER2-positive Breast Cancer Zanidatamab, Trastuzumab | JAZZ Jazz Pharmaceuticals | Phase 3 | Recruiting | 550 | Apr 28, 2028 | Registry ↗ |
| Jan 15, 2026 | A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease NCT05642442 · Parkinson Disease, Tremor Placebo, Suvecaltamide | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 169 | Oct 23, 2024 | Registry ↗ |
| Dec 16, 2025 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanc… NCT06108050 · Advanced Solid Tumor, Metastatic Solid Tumor JZP898, Pembrolizumab | JAZZ Jazz Pharmaceuticals | Phase 1 | Recruiting | 177 | Nov 30, 2027 | Registry ↗ |
| Nov 20, 2025 | VYxeoS Liposomal Italian Observational Study iN the Real Practice NCT06143839 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With M… Vyxeos liposomal | JAZZ Jazz Pharmaceuticals | — | Completed | 113 | Oct 23, 2025 | Registry ↗ |
| Oct 31, 2025 | Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis… NCT04485104 · Seizure in Participants With Tuberous Sclerosis Complex, Se… GWP42003-P | JAZZ Jazz Pharmaceuticals | Phase 3 | Terminated | 3 | Jan 28, 2025 | Registry ↗ |
| Sep 15, 2025 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract… NCT04466891 · HER2-amplified Biliary Tract Cancers ZW25 (Zanidatamab) | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 87 | Jul 28, 2023 | Registry ↗ |
| Aug 20, 2025 | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas NCT04617002 · Glioma, H3 K27M ONC201 (dordaviprone) | JAZZ Jazz Pharmaceuticals | — | Approved for marketing | — | — | Registry ↗ |
| Jul 28, 2025 | ONC201 in Adults With Recurrent H3 K27M-mutant Glioma NCT03295396 · Glioma Dordaviprone (ONC201) | JAZZ Jazz Pharmaceuticals | Phase 2 | Terminated | 73 | Dec 31, 2022 | Registry ↗ |
| Jul 24, 2025 | A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Sev… NCT05122650 · Essential Tremor JZP385, Placebo | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 420 | May 30, 2024 | Registry ↗ |
| May 25, 2025 | An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced… NCT04578444 · HER2-Positive Advanced Biliary Tract Cancer Zanidatamab | JAZZ Jazz Pharmaceuticals | — | No longer available | — | — | Registry ↗ |
| Mar 30, 2025 | Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in C… NCT04745026 · Autism Spectrum Disorder GWP42003-P, Placebo | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 103 | Dec 21, 2023 | Registry ↗ |
| Feb 28, 2025 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors NCT05126433 · Advanced Solid Tumor, Metastatic Solid Tumor Lurbinectedin | JAZZ Jazz Pharmaceuticals | Phase 2 | Terminated | 47 | Dec 20, 2023 | Registry ↗ |
| Feb 14, 2025 | ONC201 in Pediatric H3 K27M Gliomas NCT03416530 · Diffuse Intrinsic Pontine Glioma, Glioma, Malignant Dordaviprone (ONC201) | JAZZ Jazz Pharmaceuticals | Phase 1 | Terminated | 134 | Dec 31, 2022 | Registry ↗ |
| Feb 3, 2025 | Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Sei… NCT05288283 · Seizures Associated With EMAS GWP42003-P, Placebo | JAZZ Jazz Pharmaceuticals | Phase 3 | Terminated | 3 | Sep 28, 2023 | Registry ↗ |
| Dec 31, 2024 | A Study of JZP150 in Adults With Posttraumatic Stress Disorder NCT05178316 · Post Traumatic Stress Disorder JZP150, Placebo | JAZZ Jazz Pharmaceuticals | Phase 2 | Completed | 282 | Dec 5, 2023 | Registry ↗ |
| Dec 24, 2024 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer NCT03485729 · Endometrial Cancer Recurrent Dordaviprone (ONC201) | JAZZ Jazz Pharmaceuticals | Phase 2 | Terminated | 27 | Jan 19, 2023 | Registry ↗ |
| Dec 24, 2024 | Oral ONC201 in Adult Recurrent Glioblastoma NCT02525692 · Glioblastoma, Diffuse Midline Glioma Dordaviprone (ONC201) | JAZZ Jazz Pharmaceuticals | Phase 2 | Terminated | 84 | Apr 17, 2023 | Registry ↗ |
| Dec 11, 2024 | Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Parti… NCT04984278 · Spasticity With Multiple Sclerosis Nabiximols, Placebo | JAZZ Jazz Pharmaceuticals | Phase 3 | Terminated | 56 | Nov 11, 2022 | Registry ↗ |
| Nov 27, 2024 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers NCT02892123 · HER2-expressing Cancers ZW25 (Zanidatamab), Paclitaxel | JAZZ Jazz Pharmaceuticals | Phase 1 | Completed | 279 | Oct 31, 2024 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances